A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma

The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).

开始日期2023-10-01

申办/合作机构

Cellectar Biosciences, Inc.

[+1]

NCT04105543

/ Completed临床1期IIT

Therapeutic Combination of CLR 131 With External Beam Radiation in Head and Neck Cancer

This is a Phase 1 study of the use of an investigational drug that selectively delivers radiation to malignant tumor cells, CLR 131, in combination with external beam radiation therapy (EBRT) in subjects with locoregionally recurrent head and neck cancer. The trial will enroll up to 12 participants who are amenable to retreatment with radiation therapy. Participants who also have distant metastatic disease may be enrolled on this clinical trial, but they must have evaluable disease that will be clinically treated with radiation therapy, as per standard of care. All participants will receive a dosimetry test dose of CLR 131 to establish drug uptake by the tumor and enable Monte Carlo dose estimation based on CLR 131 SPECT/CT imaging evaluation. Participants showing uptake will receive a cumulative tumor dose of 60-70 Gy using personalized dose calculation (via Monte Carlo methods) of CLR 131 combined with external beam radiation.

开始日期2019-12-20

申办/合作机构

University of Wisconsin-Madison

[+2]

NCT03478462

/ Active, not recruiting临床1期

An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

开始日期2019-04-30

申办/合作机构

Cellectar Biosciences, Inc.

100 项与 Iopofosine I-131 相关的临床结果

登录后查看更多信息

100 项与 Iopofosine I-131 相关的转化医学

登录后查看更多信息

100 项与 Iopofosine I-131 相关的专利（医药）

登录后查看更多信息

项与 Iopofosine I-131 相关的文献（医药）

2025-11-13·Cureus Journal of Medical Science

Combined Treatment of Hyperbaric Oxygen and Anti-vascular Endothelial Growth Factor Therapy in Cilioretinal Artery Occlusion Associated With Central Retinal Vein Occlusion

Article

作者: Frazão, Sara ; Nogueira, Vanda ; Brissos, Júlio ; Pinto, Rita

We report a case of a male in his early 40s who presented with transient episodes of visual blurring and was initially diagnosed with isolated cilioretinal artery occlusion (CLRAO). Hyperbaric oxygen therapy (HOT) was initiated on the same day as the onset of the preceding episode, and six sessions had been completed when he was first examined at our department. Despite ongoing HOT, he developed worsening signs of venous stasis. Further investigation confirmed CLRAO secondary to central retinal vein occlusion (CRVO) and revealed heterozygosity for the factor V Leiden mutation. HOT was continued for two weeks, and a single intravitreal injection of bevacizumab (anti-vascular endothelial growth factor (anti-VEGF)) was administered, resulting in full and sustained anatomical and functional recovery, with visual acuity improving from 8/10 to 10/10. This case supports the benefit of anti-VEGF therapy in combined CLRAO and CRVO without exudative or neovascular complications, by promoting vasoconstriction and reducing venous permeability. It also suggests a synergistic effect with HOT by further lowering retinal venous pressure through distinct mechanisms. These findings highlight the potential benefit of addressing both retinal hypoxia and venous hypertension through the combined use of HOT and anti-VEGF therapy in selected cases of mixed retinal vascular occlusion.

2025-06-01·PEDIATRIC PULMONOLOGY

Impact of Home Oxygen Therapy for Bronchopulmonary Dysplasia on Families With Neonates: A Survey Conducted in Japan

Article

作者: Namba, Fumihiko ; Ogawa, Ryo ; Hasebe, Masaki ; Nakamura, Tomohiko ; Arimitsu, Takeshi

ABSTRACT:

Introduction:

Bronchopulmonary dysplasia (BPD) often necessitates home oxygen therapy (HOT) in children. Although HOT facilitates early hospital discharge and provides security, its impact on families remains unclear. This study examined family experiences with HOT to identify challenges and strategies for enhanced implementation.

Methods:

A web‐based survey was conducted with 113 families of children with BPD who used HOT within the past 3 years. Questions included the preparation for HOT, postdischarge challenges, and home monitoring devices.

Results:

HOT enabled early discharge; however, 42% families felt anxious upon leaving the hospital. Postdischarge life was harder than expected for 72% families, with mobility (82%) and equipment handling (82%) being major concerns. Coordination with home nursing services (55%) was helpful, whereas trial home stays (17%) and home visits (17%) were less commonly cited as beneficial. Home monitoring devices, used by 92% families, led to false alarms (75%). Despite such challenges, 99% considered it vital. A total of 26% adjusted oxygen flow independently, raising safety concerns.

Discussion:

The findings highlight the need for improved predischarge education, enhanced outpatient support, and technological advancements. Comprehensive preparation programs, improved home monitoring accuracy, and increased social awareness are essential to optimize HOT management and improve family quality of life.

2025-01-01·EBioMedicine

Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study

Article

作者: Cho, Steve Y ; Oliver, Kate ; Harari, Paul M ; Trask, Diana ; Glazer, Tiffany A ; Kimple, Randall J ; Adam, David P ; Bednarz, Bryan ; Burr, Adam ; Yu, Menggang ; Longcor, Jarrod ; Rogus-Pulia, Nicole ; Bruce, Justine Yang ; McCulloch, Timothy M ; Hill, Patrick ; Piaskowski, Shari M ; Hartig, Gregory K ; Wieland, Aaron M

BACKGROUND:

Re-irradiation of recurrent head and neck cancer (HNC) is often limited by tumour adherence to critical structures and/or radiation tolerance of critical normal tissues. Iopofosine I 131 (CLR 131) is a targeted small molecular phospholipid ether (PLE) drug conjugate that delivers iodine-131 selectively to tumour cells. We conducted a phase 1, single-centre, open-label study to determine whether CLR 131 given with reduced dose of external beam radiation therapy (EBRT) would be tolerable and feasible.

METHODS:

All participants received previous curative intent treatment with radiotherapy as primary or adjuvant treatment. Eligible participants demonstrated uptake of CLR 131 as indicated via single photon emission CT/CT (SPECT/CT) imaging following CLR 131 test dose. Participants received two therapeutic doses of CLR 131 (days 1 and 8) with SPECT/CT imaging performed to quantitate the biodistribution of CLR 131. Participants subsequently received EBRT to achieve the designated radiation dose (60-70 Gy). The primary endpoint was safety. This trial was registered with ClinicalTrials.gov, NCT04105543, and enrolment and follow-up are complete.

FINDINGS:

Twelve participants completed treatment with CLR 131 and EBRT. Eight participants experienced grade 4 non-DLT haematologic toxicities (2 anaemia, 8 leukopenia, 5 thrombocytopenia) at least probably attributed to CLR 131, consistent with the expected toxicity profile. Haematologic toxicities occurred during weeks 6-8 from the first dose of CLR 131 and resolved within three weeks without sequelae. There were no treatment-related grade 3-4 non-haematologic toxicities.

INTERPRETATION:

CLR 131 in combination with EBRT did not confer any safety concerns, and was tolerable in participants with recurrent/metastatic HNC. Myelosuppression was consistent with the known toxicity profile of CLR 131.

FUNDING:

National Institutes of HealthP50 DE026787, National Cancer InstituteP30 CA014520, National Institutes of Health1UL1TR002373, Cellectar, NCT04105543.

项与 Iopofosine I-131 相关的新闻（医药）

2026-05-11

·BioSpace

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details: Date: Thursday, May 14, 2026 Time: 8:30 am Eastern Time Toll Free: 1-800-717-1738 Conference ID: Webcast: 63374 Click HERE A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website. About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation. Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth. In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. For more information, please visit or join the conversation by liking and following us on the company’s social media channels: X , LinkedIn , and Facebook . Investor Contact: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.com

临床1期快速通道孤儿药财报临床2期

2026-05-09

·药融圈Stock Insight

核素新药，针对血液瘤：融资1.4亿美元完成

▲5月14-15日上海生物医药创新者峰会扫码报名声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。药融圈监测显示：2026年5月6日，美国纳斯达克Cellectar Biosciences（CLRB）公布 2b 期 CLOVER WaM 研究更新数据，显示iopofosine I 131用于经多线治疗的华氏巨球蛋白血症（WM）患者时，展现强效且持久的抗肿瘤活性——总缓解率（ORR）83.6%、中位缓解持续时间（DoR）17.8 个月；该研究已完成与 FDA 标准一致的≥12 个月随访，为加速批准路径提供关键支持。公司同时完成超额认购融资，最高可达 1.4 亿美元，资金将用于确证性试验开展及新药上市申请（NDA）提交。 iopofosine I 131 为潜在的first-in-class 磷脂药物偶联物（PDC），靶向肿瘤组织递送放射性核素碘 - 131，用于复发 / 难治性华氏巨球蛋白血症（r/r WM），已获 FDA突破性疗法认定（BTD）。临床数据（2b 期 CLOVER WaM）：人群：重度经治（中位既往治疗线数 4，含 BTKi、CD20 单抗等）WM 患者。疗效：ORR 83.6%、主要缓解率（MRR）61.8%、DoR 17.8 个月，疗效持久且跨亚组一致。随访：≥12 个月 FDA 标准随访完成，支持加速批准申报。药融圈监测显示：公司其他在研的候选新药有CLR 121225，核素Ac-225 ，靶向治疗胰腺癌等；CLR 121125，一个发射俄歇电子的I-125项目，靶向如三阴性乳腺癌、肺癌和结直肠癌等等。参考资料：药融圈数据；；ing-first-and-best-in-class-clinical-adc-pipeline/； http://www.marketscreener.com； https://www.businesswire.com； www1.hkexnews.hk/； https://clinicaltrials.gov/study/；；等等。

加速审批突破性疗法临床结果抗体药物偶联物临床2期

2026-05-07

·医道社创新药新前沿

一家小市值放射性药企，为什么可能把华氏巨球蛋白血症治疗格局撕开一道口子？——从 Cellectar Biosciences 看平台型创新药真正的护城河

医道社：传承和发展民间中医来源：海外网站作者：医道社整理版权归原作者所有，如有违规、侵权请联系我们删除！ 👆关注不迷路，更多创新药前沿资讯大家好，我是你们的创新药专业博主老汤。作为一名专注生物制药领域的分享者，我每天都泡在最新的临床报告和公司动态里。今天，我想和各位临床医生、药品研发同行们聊聊一家可能被低估的玩家——Cellectar Biosciences（纳斯达克：CLRB）。这家公司市值不高，但它的磷脂药物偶联物（PDC）平台，却像一把“手术刀”，直击Waldenström Macroglobulinemia（WM，瓦尔登斯特罗姆巨球蛋白血症）这个“隐形杀手”的要害。更重要的是，它不只是针对WM，而是构建了一个可复制的“肿瘤递送操作系统”，从血液瘤扩展到实体瘤，潜力巨大。为什么说Cellectar值得我们这些专业人士深挖？因为在WM后线治疗几乎“无药可用”的现实下，他们的iopofosine I 131（CLR 131）在CLOVER-WaM研究中交出了ORR 83.6%、中位DOR 17.8个月的硬核数据。这不是科幻，而是基于2024-2026年真实临床事实。更震撼的是，这个平台解决了传统疗法的痛点：耐药、毒性和低响应率。接下来，我结合ASH会议摘要、公司演示和行业报告，逐一拆解技术、数据、公司壁垒和未来路径。咱们一步步来，看看这家公司为什么可能成为radiopharma赛道的“平台型黑马”。第一部分：WM的残酷现实——为什么后线患者急需新武器？ WM是一种罕见的B细胞恶性肿瘤，美国每年新诊断约1500-1900例，总患病率约2.6万。但复发/难治（r/r）患者高达1.15万，其中第三线及以上患者约5700人（基于Cellectar 2019-2023年内部分析）。更棘手的是，BTK抑制剂（BTKi，如zanubrutinib）已成为一线标准，但BTKi后患者无FDA批准疗法，>60%被迫用非批准的“旧药重炒”，响应率仅4-12%（Komodo Health真实世界数据）。患者中位既往治疗线数达4线，耐药率高达77%（BTKi暴露后），传统化疗或单抗（如利妥昔）往往响应浅、持续短、毒性高。 Jefferies 2025年报告指出，WM全球r/r市场潜力超100亿美元，但缺乏深层持久响应（CR率<10%）和固定疗程选项。临床医生们都知道，患者从“终身服药”的枷锁中解脱是最大痛点，而Cellectar的iopofosine I 131正好击中这里：4次30分钟输注的“短平快”方案，却实现DOR 17.8个月（远超BTKi的12-15个月，INNOVATE研究数据）。这不是运气，而是PDC平台的结构性创新——从“外部打击”到“内部崩解”，让WM治疗从绝望转向希望。第二部分：PDC平台的硬核壁垒——不是简单靶向，而是“入侵”肿瘤的共性弱点 Cellectar的核心不是“又一个放射性药”，而是PDC平台：用肿瘤细胞膜上的脂筏（lipid rafts）作为“通用入口”，精准递送不同载荷。这套系统本质上是“可编程的肿瘤递送平台”，解决传统ADC的难题——表面受体逃逸、低响应率（30-50%）和缺乏旁观者效应。简单说，脂筏是癌症信号传导、增殖和耐药的“指挥中心”。《Molecular Cancer Research》（2020年综述）显示，>90%肿瘤中脂筏过表达，稳定期长达10天（正常细胞仅毫秒级），是“泛癌靶点”。PDC机制震撼：磷脂醚（PLE）载体模拟细胞膜脂质，“伪装”嵌入脂筏，经跨膜翻转进入细胞质，释放载荷（如I-131 β发射体）。这绕过内吞体降解，实现>60%细胞内递送率（Cellectar MBCD预处理实验，脂筏破坏后摄取降60%）。更牛的是，多模态载荷：无需重设计，就能切换β发射（I-131，半衰期8天）、α发射（Ac-225）和Auger电子（I-125）。在胰腺癌模型（BxPC-3，500nCi剂量），肿瘤体积减>80%。相比ADC，PDC不依赖单一突变，在MYD88野生型WM患者（29%）中响应率仍达81%。研发人员会欣赏这点：它像“操作系统”，同一逻辑接小分子、寡核苷酸或生物大分子，构建“肿瘤内递送体系”。 iopofosine I 131专为血液肿瘤设计，CNS穿透强（Phase 1数据），《Nature Reviews Drug Discovery》（2023年）预测TRT市场2028年达150亿美元，Cellectar的“快速同位素切换”领先一步。第三部分：CLOVER-WaM数据深度解读——从ORR到子组，持久响应征服难治人群平台验证离不开临床。CLOVER-WaM（NCT02952508）是国际多中心、开放标签Phase 2b研究，纳入65例中位年龄70岁的WM患者（93.8%白人，71% BTKi暴露）。mITT人群（n=55，总剂量≥60mCi）数据亮眼： ·ORR：83.6%（95%CI 71.0-92.3%） ·MRR：61.8%（超20%阈值，Clopper-Pearson法） ·VGPR/CR：14.5% ·DCR：98.2% ·中位DOR：17.8个月（18个月随访，72%响应者无进展） ·中位PFS：13.5个月 2024 ASH年会（Blood 2024;144:861）首报MRR 56.4%、ORR 80%；2026年GlobeNewswire更新确认耐药性。震撼对比：远超RCD方案（ORR~50%，DOR<12个月，ASPEN研究）。最打动临床医生的，是子组数据： ·BTKi后队列（n=39）：MRR 64.1%，DOR 18.2个月，PFS 15.9个月 ·BTKi难治队列（n=33）：MRR 63.6%，DOR 18.2个月，PFS 14.8个月这说明iopofosine I 131在“无路可走”人群中仍有稳定活性，不是“钻空子”，而是真正持久响应（CR 10%+ vs BTKi 0%）。固定疗程设计（4次短输注）避免长期毒性累积和依从性问题，对患者和支付体系友好。ASCO 2026年将呈BTKi后子组，进一步夯实。第四部分：安全性与治疗哲学——可控毒性+有限疗程，差异化卖点放射药常被诟病毒性大，但Cellectar数据证明：毒性可预期、可管理。TEAE以骨髓抑制为主： ·血小板减少：81.5% G3+ ·中性粒减少：66.2% G3+ ·感染：<10% ·非血液毒性：疲劳33.8%（多G1-2），无显著出血，所有患者恢复。比BTKi出血风险（>20%）和化疗感染风暴（>30%）安全太多。这符合放疗药理：强调“邻近杀伤”（bystander effect），从“持续压制”转向“有限疗程、深度缓解”。研发者会看到，这不仅是临床优势，还便于联合/序贯治疗。第五部分：公司全景与护城河——从监管快车道到供应链，平台裂变潜力 Cellectar成立于2012年，总部新泽西，高管95年经验（CEO James Caruso掌管多家生物公司）。2025年10月融资1.4亿美元（超额，现金1.26亿，支撑至2027年），市值~2亿美元，但管道丰富，IP覆盖放射偶联物、小分子等。监管路径：iopofosine I 131获FDA Breakthrough Therapy（2025年6月，WM，批准率79%）和EMA PRIME（80%）。CLOVER-WaM满足加速批准（MRR+DOR≥12个月），2026 Q3 EU CMA提交，2027商业化；US加速批准预备案，Phase 3（200例，PFS vs RCD，成本4200万）2026 Q4启动。管线多样：不止WM，覆盖7+适应症。 ·CLR 125（I-125 Auger，TNBC Phase 1b，Mayo Clinic）：肿瘤吸收5mGy/MBq（正常<1），无器官毒性，市场110亿。 ·CLR 225（Ac-225 α，胰腺癌Phase 1）：PANC-1模型PFS>56天，肿瘤减容，市场100亿。 ·早期：At-211（TNBC，40uCi根除）、Lu-177（乳腺癌，完全回归）；MM/DLBCL/NHL ORR 30%（四类难治），pHGG获儿科审查券。总市场超500亿。制造供应链：公斤级GMP API（>5年供应），多源CMO、同位素供应商，48小时全球配送。避开Lutathera（Lu-177瓶颈）风险，合作伙伴如Takeda、Janssen加速资金。这不是“单点资产”，而是平台型：验证脂筏递送后，复制到多癌种，像Moderna mRNA般裂变。WM市场：美国26,000患者，11,500 r/r，4,700三线+。第六部分：深度风险与震撼观点——为什么Cellectar能颠覆？平台想象力几何？当然，不能只说亮点。风险真实： ·骨髓抑制需持续管理。 ·Phase 3 PFS优越性（24-30个月）必须验证。 ·商业化待考（销售≠临床）。 ·资金压力（多项目并行）。 ·监管节奏变数（BTD/PRIME不等于自动批）。但震撼观点：PDC是paradigm shift，从“靶点变异”到“结构性入侵”，在难治WM实现98.2% DCR，挑战“无药可用”。类似ADC革命（Enhertu ORR 70%），Cellectar占TRT市场10%即15亿营收。真正可怕：跨癌种复制——TNBC、胰腺、DLBCL、MM、儿高胶。如果成功，它从“WM药企”变“通用平台公司”，估值逻辑重定价。结语：Cellectar，radiopharma的“下一个黑马”——临床与研发的行动信号 Cellectar的PDC平台，用数据说话（ORR 83.6%、DOR 17.8个月），用事实征服（BTD+1.4亿融资）。在WM“隐形杀手”肆虐时，它点亮希望。临床医生，期待NDA和Phase 3；研发人员，关注平台扩展；投资者，盯紧CLRB。创新药革命，由我们见证——如果你有临床经验或管线洞见，欢迎评论区交流！（数据来源：Cellectar 2026公司演示、ASH 2024摘要、GlobeNewswire 2026新闻、Jefferies报告、ClinicalTrials.gov。所有观点基于公开真实事件，非投资建议。）

多肽偶联药物放射疗法专利侵权

100 项与 Iopofosine I-131 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15244

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
巨球蛋白血症	临床3期	美国	Cellectar Biosciences, Inc.	-
慢性淋巴细胞白血病	临床2期	美国	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	澳大利亚	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	巴西	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	捷克	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	芬兰	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	法国	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	希腊	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	以色列	Cellectar Biosciences, Inc.	2017-07-26
慢性淋巴细胞白血病	临床2期	西班牙	Cellectar Biosciences, Inc.	2017-07-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02952508 (ASH2024) 人工标引	临床2期	巨球蛋白血症三线	65	Iopofosine I 131 15 mCi/m2	獵齋衊鹹鬱鏇襯窪鹹窪(襯壓範衊蓋夢窪壓鹽範) = occurred in 1 patient due to bacterial sepsis 窪衊選選壓網夢憲選遞 (餘糧觸觸繭衊觸繭憲鬱 ) 更多	积极	2024-12-09
NCT04105543 (Pubmed \| NEWS)	临床1期	局部晚期头颈部鳞状细胞癌	12	Iopofosine I-131+放疗	夢淵膚夢鬱願繭鹽製鏇(遞遞糧窪構製醖範鏇積) = 壓衊醖壓蓋醖遞壓築膚繭積艱選願鏇願鑰憲齋 (蓋選製膚顧膚網艱範顧 ) 更多	积极	2024-03-04
NCT02952508 (CLOVER-WaM, Corporate Publications) 人工标引	临床2期	巨球蛋白血症	50	Iopofosine I 131	願齋廠獵餘衊範鹹選憲(選簾糧窪簾遞網積壓壓) = 夢夢膚鬱蓋窪鏇網鹽築鏇觸願窪積鑰繭艱壓網 (鏇鏇醖糧製襯積鑰製觸, 44.5 ~ 75.8) 达到更多	积极	2024-01-08
NCT02952508 (CLOVER-1, Literature) 人工标引	临床2期	复发性多发性骨髓瘤末线	7	CLR-131+dexamethasone (total dose ≥60 mCi)	鑰窪鏇願醖壓淵餘夢構(憲築鏇簾製齋製夢積鑰) = 壓願鏇糧艱鬱築選憲簾憲齋鏇網蓋餘觸獵顧蓋 (積鹹窪顧築構窪齋範壓 ) 更多	积极	2022-09-06
NCT02952508 (CLOVER-1, Literature) 人工标引	临床2期	复发性多发性骨髓瘤末线	7	CLR-131+dexamethasone (total dose <60 mCi)	-	积极	2022-09-06
NCT02952508 (CLOVER-1, ASCO2021)	临床2期	淋巴浆细胞性淋巴瘤 \| 套细胞淋巴瘤 \| 慢性淋巴细胞白血病 ... 更多	6	CLR 131	繭蓋顧築構醖襯簾鏇範(製觸鹹衊廠築簾襯鏇積) = anaemia (66%) 艱鹹糧鏇糧襯顧壓構齋 (夢鏇鏇餘糧構鏇艱衊選 ) 更多	-	2021-05-28
NCT02952508 (ESMO2019) 人工标引	临床2期	复发性弥漫性大B细胞淋巴瘤	6	CLR-131	膚遞壓遞窪鑰築鏇蓋糧(齋糧鬱選鏇醖鹽醖繭積) = 襯夢觸願衊淵齋構壓網簾壓襯齋鹹憲齋構範廠 (顧選餘鏇選網鏇淵積糧 ) 更多	积极	2019-09-28
AACR2018	临床2期	-	-	Fractionated injections of CLR 131	壓壓廠憲憲遞餘顧窪鏇(襯窪製觸遞獵顧鏇蓋醖) = 壓鬱獵鹽衊衊製鬱餘鑰網蓋鹹選襯顧憲鏇衊醖 (鬱鬱窪獵製鹹願獵糧願 )	-	2018-07-01
AACR2018	临床2期	-	-	Standard dosing of bortezomid	壓壓廠憲憲遞餘顧窪鏇(襯窪製觸遞獵顧鏇蓋醖) = 鬱艱醖選觸夢築鹹選觸網蓋鹹選襯顧憲鏇衊醖 (鬱鬱窪獵製鹹願獵糧願 )	-	2018-07-01
NCT02278315 (ASH 12016 \| ASH 22016) 人工标引	临床1期	多发性骨髓瘤	8	dexamethasone+I-131-CLR1404	獵鑰積蓋壓構齋淵鹹鹹(衊廠繭願鬱簾選願遞簾) = 壓構簾淵網壓衊願廠願願夢憲築積願簾憲餘糧 (齋淵衊構選衊淵範簾獵 )	积极	2016-12-02
NCT02278315 (ASH 12016 \| ASH 22016) 人工标引	临床1期	多发性骨髓瘤	8	dexamethasone+I-131-CLR1404	齋糧選廠廠繭壓製觸壓(壓齋廠鬱鏇醖襯鏇餘獵) = 鹹網築衊築襯艱鏇製醖鑰遞襯衊顧窪膚製遞繭 (艱鹽網獵壓遞夢範鏇繭 ) 更多	积极	2016-12-02
NCT00925275 (Pubmed \| PLoS One)	临床1期	晚期恶性实体瘤	8	131I-CLR1404	顧顧膚製蓋範餘製繭鹽(製夢鏇餘壓艱餘顧鏇夢) = 餘憲夢醖願餘範襯製衊遞鹽觸網獵鑰觸窪簾簾 (鏇範願糧衊願鏇鏇顧遞 ) 更多	-	2014-11-17
NCT01495663 (ASCO2014)	临床1期	HR阳性/HER2低表达实体瘤	12	Phospholipid ether [<sup>131</sup>I]-CLR1404	廠鏇壓廠廠壓鹽襯糧簾(簾獵窪構淵憲顧願構鏇) = 憲鑰製繭鑰廠艱醖選廠憲範顧淵廠壓襯齋糧襯 (蓋繭製築構餘壓築顧壓 )	-	2014-05-20